Category: Investment, Biotech, Pharma
Biotech Stock Alert: Sunshine Biopharma (OTCQB: SBFM) Reports Additional IND-Enabling Study: Adva-27a Is Found to Be Effective Against Multidrug Resistant Uterine Cancer Cells
Ideas get bigger when you share them...
Visit this company: Sunshine Biopharma Inc.
December 12, 2012 (Investorideas.com Newswire) Sunshine Biopharma Inc. (OTCQB: SBFM), a pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer, today announced that it has completed a new IND-Enabling study in which Adva-27a, the Company's flagship oncology drug candidate, was found to be effective at killing Multidrug Resistant Uterine Cancer Cells in vitro. The study was carried out in MES-SA/Dx5, a Uterine Sarcoma cell line that has become multidrug resistant through the use of a commonly administered chemotherapy drug, Doxorubicin. Adva-27a was able to kill these cells with an IC50 of less than 8 micromolar, a very pharmacologically favorable drug concentration. Sunshine Biopharma had previously reported that Adva-27a is also capable of effectively killing Multidrug Resistant Breast Cancer Cells (MCF-7/MDR) and Small-Cell Lung Cancer Cells (H69AR) in vitro.
"This brings to three the total number of Multidrug Resistant Cancer types that Adva-27a can destroy. Other chemotherapy drugs are completely ineffective against these cancers," said Dr. Steve N. Slilaty, CEO of Sunshine Biopharma. "This confirms the general effectiveness of Adva-27a against Multidrug Resistant Cancer," he added.
About Sunshine Biopharma Inc.
Sunshine Biopharma is an early stage pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer. Sunshine Biopharma recently announced that it has initiated IND-Enabling studies for its lead antitumor compound, Adva-27a.
Safe Harbor Forward-Looking Statements
To the extent that statements in this press release are not strictly historical, including statements as to revenue projections, business strategy, outlook, objectives, future milestones, plans, intentions, goals, future financial conditions, future collaboration agreements, the success of the Company's development, events conditioned on stockholder or other approval, or otherwise as to future events, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements contained in this release are subject to certain risks and uncertainties that could cause actual results to differ materially from the statements made.
For Additional Information
Camille Sebaaly, CFO
Sunshine Biopharma Inc.
Direct Line: 514-814-0464
Published at Investorideas.com newswire
Disclaimer/ Disclosure: The Investorideas.com is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising. Disclosure : SBFM is an expired client on investorideas.com m and is long 144 stock. http://www.investorideas.com/About/Disclaimer.asp
BC Residents and Investor Disclaimer: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894
800-665-0411 - Source – www.Investorideas.com